Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine
Jean‐Jacques Grob(Aix-Marseille Université), Axel Hauschild(University Hospital Schleswig-Holstein), Patricia Haney(GlaxoSmithKline (United States)), Salvador Martín‐Algarra(Clinica Universidad de Navarra), Mayur M. Amonkar(GlaxoSmithKline (United States)), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Beloo Mirakhur(GlaxoSmithKline (United States)), Wilson H. Miller(Jewish General Hospital), Cornelia Mauch(University Hospital Cologne), Kelly M. Grotzinger(GlaxoSmithKline (United States)), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Bogusława Karaszewska(State University of Applied Sciences in Konin), S. Swann(GlaxoSmithKline (United States)), Michael Millward(University of Western Australia), Lev Demidov(Heidelberg University), Vicki Goodman, Eckhart Kämpgen(Universitätsklinikum Erlangen)
Cited by 55
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k